Abstract: Objective : To evaluate the efficacy and toxicity of combination chemotherapy of Mitomycin plus vindesine plus cisplatin, vinorelbine plus cisplatin and paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods : One hundred-fourteen patients with non-small cell lung cancer were enrolled. Thirty-six patients received MVP (mitomycin 6mg/m², day1, vindesine 3mg/m², day1, 8 and cisplatin 80mg/m², day3 every 28 days). Forty-one patients received NP (vinorelbine 25mg/m² , day1, 8 and cisplatin 80mg/m², day3 every 28 days). Thirty-seven patients received TP(paclitexl 175mg/m², day1 and cisplatin 80mg/m², day3 every 28 days). It lasted for two cycles at lest. Results : The objective response rate was 33.2% in the MVP arm, 34.1% in the NP arm and 40.5% in the TP arm. Median survival was 8.2 months, 7.1 months and 9.1 months.1 -year survival rate was 30.5%, 34.1%, 37.8% respectively. The main response were myelosuppression, anorexia, nausea/vomiting on the MVP arm, myelosuppression, anorexia, nausea/vomiting, phlebitis on the NP arm and myelosuppression, nausea/vomiting, nephrotoxicity, shed on the TP arm. Conclusion : In the present study, no significant difference was observed in response rate, median survival or 1 -year survival rate between the MVP, NP and TP regimens. The side effects were tolerable.